The Cancer Immunotherapy Program currently has the following clinical trials open for enrollment (please click on the links below for detailed summary and eligibility criteria for each trial in PDF format).

Cancer Immunotherapy Clinical Trial Protocols

  • Metastatic Lung Cancer (NSCLC)(RWH 349-32): A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Non-Small Cell Lung Cancer
  • Solid Tumor (RWH 111-32): A Phase I Study of Anti-CD3 x Cetuximab-Armed Activated T Cells, Low Dose IL-2, and GM-CSF for EGFR-Positive, Advanced Solid Tumors